[PERSON]
Maziar Doustdar
Featured in 1 tracked story · first seen
Situations
Novo Nordisk pivots strategy to counter patent cliff
107 clusters · 526 sources · last updated
Latest: Novo Nordisk unveils 2030 growth strategy amid patent concerns
Novo Nordisk is implementing a strategic reset to address long-term growth concerns and the looming patent expiration of semaglutide, the active ingredient in Ozempic and Wegovy. During a 2026 Capital Markets Day in Lond